Journal article

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

G Paul Amminger, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam R Schafer, Maximus Berger, Nilufar Mossaheb, Monika Schloegelhofer, Stephan Smesny, Ian B Hickie, Gregor E Berger, Eric YH Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Roessler, Swapna Verma, Andrew Thompson, Alison Ruth Yung, Patrick D McGorry



BACKGROUND: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants. METHODS: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) colle..

View full abstract


Awarded by Stanley Medical Research Institute

Awarded by National Health and Medical Research Council Australia

Funding Acknowledgements

This work was supported by the Stanley Medical Research Institute (Grant No. 07TGF-1102 [to PDM, GPA, and BN]), National Health and Medical Research Council Australia (Grant No. 566529 [to PDM, IBH, ARY, and GPA], Grant No. 509388 [to GPA and PDM], Senior Research Fellowship Grant No. 1080963 [to GPA], Senior Research Fellowship Grant No. 566593 [to ARY], Career Development Fellowship Grant No. 1027532 [to BN], and Senior Principal Research Fellowship Grant No. 1060996 [to PDM]), Colonial Foundation (to PDM), and National Alliance for Research on Schizophrenia and Depression (to PDM).PDM reports receiving unrestricted research funding from AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, and Novartis and honoraria for educational activities with AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche Holding AG, and the Lundbeck Institute. The other authors report no biomedical financial interests or potential conflicts of interest.